Needham Maintains Buy on Mereo BioPharma Group, Lowers Price Target to $3
Benzinga Newsdesk 9 months ago
NewsPrice TargetAnalyst Ratings
Needham analyst Gil Blum maintains Mereo BioPharma Group (NASDAQ:MREO) with a Buy and lowers the price target from $5 to $3.
Needham analyst Gil Blum maintains Mereo BioPharma Group (NASDAQ:MREO) with a Buy and lowers the price target from $5 to $3.